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-Evidence before this study:
Data sources and searches 
© 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Two investigators searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials and 
Web of Science using the search strategy described in the online supplement. Searches were conducted 
from 2000 to 30th September 2018. No language restrictions were applied. Searches were supplemented 
with review of reference lists and by reviewing previous meta-analyses and guidelines. Clearly ineligible 
studies were excluded based on abstract review alone.   
We identified 266 references and after exclusion of non-relevant studies we identified 3 randomized 
controlled trials comparing long term treatment with macrolide antibiotics (>3 months duration) 
compared with placebo where the primary outcome was the reduction of exacerbations. We identified 
several existing aggregate meta-analyses that suggested that macrolides reduce the frequency of 
exacerbations of bronchiectasis. Neither the individual trials nor the existing meta-analyses reported on 
the effectiveness of macrolides in different subpopulations. Identifying which patients benefit from 
macrolides was identified as a key research priority in bronchiectasis. The current European Respiratory 
Society guidelines suggest consideration of macrolides for patients without Pseudomonas aeruginosa 
infection with a history of at least 3 exacerbations in the previous year.  
  
Added value of this study: 
We report the first individual patient data meta-analysis of long term macrolide therapy in 
bronchiectasis. Our data from 341 patients enrolled in randomized clinical trials in the Netherlands, New 
Zealand and Australia suggests that macrolide treatment compared to placebo for 6-12 months results 
in a 50% reduction in the frequency of exacerbations. Additional benefits included prolongation of the 
time to first exacerbation and statistically significant improvements in quality of life measured by the St 
Georges Respiratory Questionnaire. Lung function was not significantly improved. Analyses in pre-
specified subgroups including age, sex, disease severity and baseline microbiology suggested that 
macrolides effectively reduced exacerbations across all subgroups of patients. Importantly, macrolides 
had a significant and clinically meaningful impact in patients where macrolide are not currently 
considered as first line treatment, including patients with P. aeruginosa infection and patients with less 
than 3 exacerbations per year.  
  
Implications of all the available evidence: 
Our data suggests that macrolide therapy is highly effective in reducing the frequency of exacerbations 
in bronchiectasis. Given the strong evidence that exacerbations contribute to long term morbidity and 
mortality in bronchiectasis macrolides should be considered in patients with frequent or severe 
exacerbations. Current bronchiectasis guidelines recommend inhaled antibiotics as first line treatment 
for patients with P. aeruginosa infection and frequent exacerbations. In view of the high level of 
effectiveness in reducing exacerbations demonstrated by macrolides in the P. aeruginosa subgroup, and 
recent equivocal data on the effectiveness of inhaled antibiotics, macrolides may be considered as first 
line for patients with P. aeruginosa infection. The magnitude of benefit was similar in patients with 1-2 
exacerbations per year as in the subgroup with 3 exacerbations per year, in whom macrolides are 
recommended by international guidelines, suggesting an individualised discussion of the risks and 
benefits of macrolides. Macrolides have important adverse events and the potential to induce 
antimicrobial resistance and so should be used judiciously. No studies were identified with a treatment 
duration of more than 1 year and so the longer term efficacy and safety of macrolides is unknown.  
 
  
 
Summary 
Background: Bronchiectasis guidelines recommend long term macrolide treatment for patients with 3 or 
more exacerbations per year without P. aeruginosa infection. Randomized controlled trials (RCTs) 
suggest that long term macrolide treatment can prevent exacerbations in adult patients with 
bronchiectasis but these individual studies have been too small to conduct meaningful subgroup 
analyses. Individual patient data (IPD) meta-analysis could explore macrolide benefit in subpopulations 
including those where macrolide therapy is not currently recommended. 
Methods: MEDLINE, Embase, the Cochrane Central Register of Controlled Trials and Web of Science 
were searched to identify randomized controlled trials of macrolide antibiotics for at least 3 months 
with a primary outcome of bronchiectasis exacerbations. IPD meta-analysis was performed using fixed 
effects models adjusting for age, sex, FEV1 and trial.  
Findings: IPD was obtained for 341 participants in 3 RCTs. Macrolide antibiotics reduced the frequency of 
exacerbations adjusted incidence rate ratio (IRR) 0.49 95% CI 0.36-0.66,p<0.0001, improved the time to 
first exacerbation, (hazard ratio 0.46 95% CI 0.34-0.61,p<0.0001) and were associated with improved 
quality of life measured by the St Georges Respiratory Questionnaire (mean improvement 2.9 points 
(95% CI 0.03 to 5.8,p=0.048). Pre-specified subgroup analyses revealed a reduced frequency of 
exacerbations in all pre-specified subgroups including a high level of benefit in patients with 
Pseudomonas aeruginosa infection (IRR 0.36 95% CI 0.18-0.72,p=0.004) and in patients with less than 3 
exacerbations per year (IRR 0.37 95% CI 0.16-0.88,p=0.02).  
 
Interpretation: Long-term macrolide treatment significantly reduces the rate of exacerbations in 
patients with bronchiectasis with similar benefits observed in all subgroups based on patient 
characteristics.  
 
 
 
 
 
Background 
Bronchiectasis is a common chronic disease associated with frequent respiratory tract infections, 
chronic symptoms of cough and sputum production.1 The disease has a devastating impact on patients’ 
quality of life.2 In addition exacerbations of bronchiectasis, which are characterised by increases in 
symptoms requiring antibiotic treatment, are a major driver of disease progression and associated 
mortality.3,4 
Bronchiectasis is characterised by a “vicious vortex” of bacterial infection, airway inflammation and 
impaired mucociliary clearance which each interact to promote lung damage.5,6 There are few evidence 
based treatments for bronchiectasis as reflected in the recent European Respiratory Society 
bronchiectasis management guidelines which were unable to recommend any pharmacotherapy with a 
high quality of evidence.7 Macrolide antibiotics are among the most widely used chronic treatments to 
prevent exacerbations in bronchiectasis.8,9 They are particularly attractive because there is evidence 
they target each of the key components of bronchiectasis pathophysiology.  In addition to reducing 
bacterial burden, they have well established immunomodulatory effects which include suppression of 
neutrophil mediated lung damage, and they also enhance cilia function to promote mucociliary 
clearance.10-12 
A number of randomized controlled trials have demonstrated that the macrolide class of antibiotics 
significantly reduces exacerbations in bronchiectasis. 13-16 Meta-analysis of these trials based on 
aggregate data suggest a clear reduction in the frequency of exacerbations with macrolide therapy along 
with other benefits. For example the meta-analysis of Gao et al identified 9 trials with 559 participants 
of which 6 were conducted in adults.17,18 Macrolide therapy reduced the frequency of exacerbations by 
58%, and reduced the proportion of patients experiencing exacerbations with slight improvements in 
FEV1 and quality of life.17 Macrolides, however, were associated with increased adverse events such as 
diarrhoea and abdominal discomfort and also with an increased risk of antibiotic resistance.9,13 Hearing 
loss and cardiovascular effects have been detected in other patient populations but were not observed 
in bronchiectasis trials.9,19,20 Based on this, the most recent Cochrane review called for further research 
to identify specific patient groups who are most responsive to macrolides.21 An ERS/EMBARC consensus 
statement, based on a survey of over 100 bronchiectasis experts and over 1000 patients, published in 
2016 identified “further studies to define the optimal patient population to benefit from long-term 
macrolide therapy” as one of the 22 key research priorities in bronchiectasis.22 
 We therefore undertook an individual participant data (IPD) meta-analysis of studies of long-term 
macrolides in adults with the objective of identifying responsive patient subgroups. 
 
Methods 
We performed a systematic review and one-step and two-step meta-analysis of individual participant 
data. The review protocol was prospectively registered with the PROSPERO international register of 
systematic reviews- registration number CRD42018102908. Systematic review and meta-analyses are 
exempt from research ethics committee review in the UK. Findings are reported according to the 
PRISMA guidelines for IPD meta-analysis.23 
Study selection 
Double blind placebo-controlled randomized controlled trials of macrolide antibiotics in adult patients 
with bronchiectasis were eligible for inclusion if they also fulfilled the following criteria: long term 
treatment, defined a-priori as treatment for at least 3 months based on the previous ERS guidelines and 
recording of exacerbation rate as a primary or secondary outcome.7 Studies in patients with cystic 
fibrosis bronchiectasis were excluded.  
Data sources and searches 
Two investigators (JDC and MLC) searched MEDLINE, EMBASE, the Cochrane Central Register of 
Controlled Trials and Web of Science using the search strategy described in the online supplement. 
Searches were conducted from 2000 to 30th September 2018. No language restrictions were applied. 
Searches were supplemented with review of reference lists and by reviewing previous meta-analyses 
and guidelines. Clearly ineligible studies were excluded based on abstract review alone.  
Definition of outcomes 
The primary outcome of the meta-analysis was the frequency of exacerbations requiring treatment with 
antibiotics. This was selected based on clinical and regulatory opinion that this is the most important 
clinical endpoint in bronchiectasis studies.4,24,25 Exacerbation definitions varied across different studies 
and therefore a-priori definitions were used based on prescription of antibiotics for an increase in 
respiratory symptoms. Secondary endpoints were time to the first exacerbation, the proportion of 
patients experiencing an exacerbation, change in quality of life using the St.Georges Respiratory 
Questionnaire (SGRQ) and change in forced expiratory volume in 1 second (FEV1) in millilitres.  
Data synthesis and analysis 
Our IPD meta-analysis approach utilised published guidelines.26 Initially, all studies were re-analysed 
separately to replicate the results of the original reported studies, using the methodology described in 
the respective publications. Any discrepancies were resolved with the original study authors. We then 
performed a one-step and two-step meta-analysis of the primary outcome, exacerbation frequency. This 
was analysed using a negative binomial model with time in study as an offset. Results were expressed as 
incident rate ratios (IRRs) with associated 95% confidence intervals (95% CI). For secondary outcomes 
we performed one-step meta-analysis only. In the one-step analysis approaches, IPD from studies were 
modelled with fixed effects adjusting for age, sex, FEV1 at baseline and trial to obtain the pooled 
intervention effect estimate. Adjustment for trial as a fixed effect was pre-specified following literature 
review based on the very similar inclusion criteria, patient characteristics, design and outcomes used in 
all three studies ultimately included in the meta-analysis. A sensitivity analysis for the primary outcome 
was performed controlling for study as a random effect. To check the validity of the confidence intervals 
around the estimates a non-parametric bootstrap was performed. Time to next exacerbation was 
analysed using Cox proportional hazards regression adjusted for age, sex and FEV1 at baseline as 
covariates and with study as a stratification variable. The proportional hazards assumption was 
confirmed by inspection of log minus log plots.  Continuous outcomes were analysed using a generalized 
linear model with the addition of baseline value of the endpoint as an additional covariate. In addition to 
the analysis of quality of life as a continuous outcome variable we performed a responder analysis using 
logistic regression with the response being an improvement of 4 points or more in the SGRQ score, the 
reported minimum clinically important difference for this score.24,25 For the two-step approach to the 
primary outcome the individual participant data was analysed using a negative binomial regression with 
adjustment for age, sex and baseline FEV1 to produce an estimate of treatment effect for each study. 
Meta-analysis was then performed using the Mantel-Haenszel method, and heterogeneity was reported 
using the I2 statistic. Analyses were performed using R version 3.4.0 and Statistical Package for the Social 
Sciences (SPSS) version 22. The two step meta-analysis was performed using Review Manager 5 
(Cochrane Collaboration). 
Subgroup analyses 
A key objective of this study was to identify subgroups of patients in which macrolides had a differential 
effect. Interactions were evaluated by including interactions terms in the appropriate models as 
described above. Pre-specified subgroup analyses were conducted for each of the primary and 
secondary endpoints using one-step meta-analysis only. Subgroups were defined as follows 
Age groups <50 years, 50-69 years and >70 years; sex (male and female); prior exacerbation frequency 
(1-2 per year, 3 per year and >4 per year); smoking status (never and ex or current smoker); inhaled 
corticosteroid use as baseline; body mass index at baseline (<21, 21-24.9, 25-29.9 and >30); aetiology 
(idiopathic and post-infective aetiology and other aetiologies); C-reactive protein at baseline (<2mg/L, 2-
5mg/L, 5.1-10mg/L and >10mg/L); Baseline FEV1 % predicted (>80%, 50-79%, <50%); SGRQ total score 
(<30, 30-49, >50); Pseudomonas aeruginosa in sputum culture at baseline. Statistical significance was 
inferred for subgroup effects in which the p-value for interaction was less than 0.05.  
Role of the funding source 
All funders of the study had no role in study design, data collection, data analysis, data interpretation or 
writing of the report. The corresponding author had full access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
 
 
 
  
Results  
Study inclusion and individual participant data 
Figure 1 shows the selection of studies for analysis. Two hundred and thirty four potentially eligible 
studies were identified. After exclusion of 231 manuscripts that did not meet the inclusion criteria, 3 
double blind randomized placebo controlled trials with 341 participants were included. We sought IPD 
for these 3 trials and obtained data for all eligible participants.  
Study and participant characteristics 
The three included RCTs were conducted in the Netherlands, New Zealand and Australia. Two trials 
compared azithromycin vs placebo while one trial compared erythromycin vs placebo. Randomized 
participants were aged 18 to 80 years and 222/341 (65.1%) patients were female.  Study and participant 
characteristics are shown in table 1. The final analysis included 173 patients treated with macrolide and 
168 patients treated with placebo.  
Risk of bias 
Details of the risk of bias assessment are shown in appendix table E1. All RCTs contributing data to the 
IPD meta-analysis were assessed as being at low risk of bias. 
Primary outcome- frequency of exacerbations  
In the one step meta-analysis long term macrolide therapy was associated with a marked reduction in 
frequency of exacerbations (IRR 0.49 95% CI 0.36-0.66,p<0.0001). Sensitivity analyses were performed 
excluding the adjustment for baseline covariates and not including the offset which identified similar 
results (Table E2). Likewise, controlling for study as a random effect did not impact on the overall 
conclusions. A non-parametric bootstrap of the data produced similar confidence intervals to those 
obtained directly from the model.  
The two step meta-analysis identified a similar result to the one step approach, IRR 0.51 (0.37-
0.69,p<0.0001) with no heterogeneity, I2=0% (figure E1).  
Results of subgroup analyses for frequency of exacerbations 
The results of the subgroup analyses based on patient characteristics are shown in table 2. None of the 
subgroup analyses showed statistically significant interactions with the exception of aetiology.   
Non-significant trends suggested improved response with increasing age, extremes of BMI and 
increasing systematic inflammation. Patients with P. aeruginosa also showed a statistically significant 
response to macrolide treatment, (IRR 0.36 95% CI 0.18-0.72,p=0.004). Response showed no significant 
interaction based on sputum culture. H. influenzae was the second most frequent pathogen and this 
subgroup showed no differential response, (IRR 0.40 95%CI 0.10-1.69,p=0.21). No significant difference 
was observed in the IRR between different strata of baseline exacerbation frequency. Absolute risk 
reductions in each strata are shown in table E3 online. The event based number needed to treat was 
calculated as 1.0 for patients with 4 or more exacerbations per year, 1.7 for patients with 3 
exacerbations in the previous year and 1.5 for patients with a history of 1-2 exacerbations per year in 
the prior year. 
Secondary outcomes- time to first exacerbation 
Time to first exacerbation was significantly prolonged with macrolide treatment, adjusted hazard ratio 
0.46 95% CI 0.34-0.61,p<0.0001. The model derived median times to first exacerbation were 98 days in 
the placebo groups and 280 days in the macrolide treated groups. Table 3 shows time to first 
exacerbation in the pre-specified subgroups. 
 
Secondary outcomes- St Georges Respiratory Questionnaire 
We identified a statistically significant improvement in quality of life with macrolide treatment vs 
placebo of 2.93 points (95% CI 0.03 to 5.83,p=0.048). The number of patients achieving a greater than 4 
point improvement in SGRQ was also increased with macrolide therapy, Odds ratio 1.61 (95% CI 1.02-
2.54,p=0.042). The strongest relationships with improvement in symptoms were observed when 
comparing those with idiopathic/post-infective aetiology against other aetiologies, where the 
interaction was statistically significant. Non-significant trends towards greater QoL improvement were 
seen in older patients, females, ex-smokers, inhaled corticosteroid users, and patients with BMI 
>30mg/k2 (figure 2, Table E4).  
 
 
Secondary outcomes: FEV1 change from baseline 
Macrolides were not associated with a significant improvement in FEV1, however a non-significant 
improvement of 67ml at 1 year was observed (95% CI -22m to 112ml, p=0.14). The subgroup effects on 
lung function are shown in figure 3. Only the interaction between idiopathic/postinfective aetiology and 
other aetiologies was significant at p=0.03. The highest responses were seen in inhaled corticosteroid 
users, aetiologies other than idiopathic/postinfective, higher systemic inflammation and P. aeruginosa 
at baseline (Figure 3, Table E4).  
 
 
 
  
Discussion 
This IPD meta-analysis has demonstrated that macrolides reduce the frequency of exacerbations by 51% 
over 6-12 months and are associated with a significant improvement in quality of life measured using 
the SGRQ. The mean improvement in quality of life did not exceed the minimum clinically important 
difference but the proportion of patients achieving a clinically meaningful improvement in quality of life 
was increased with macrolide vs placebo. The findings of this study agree with the findings of the 
original BAT, BLESS and EMBRACE studies and the results of prior meta-analyses.13-15,17,21 The advantage 
of IPD meta-analysis is the ability to standardise the analysis and reporting of each trial. Previous meta-
analyses have been limited in their assessment of frequency of exacerbations, time to first exacerbation, 
and quality of life and other endpoints because of different methods of reporting in the 3 studies we 
reviewed. The most recent Cochrane systematic review of macrolide antibiotics in bronchiectasis could 
not fully analyse the frequency endpoint due to heterogeneous reporting of data and therefore limited 
exacerbation analysis to the proportion of patients experiencing one or more exacerbations.21 Previous 
estimates of the effect of quality of life and lung function were also based on incomplete data. 
Therefore our IPD meta-analysis provides a more accurate assessment of the benefits of macrolide 
treatment in adults with bronchiectasis. The most novel aspect of our study, however, is the ability to 
examine subgroup effects. Subgroup analyses can provide useful information for clinicians who need to 
decide how to use macrolides in practice, but should be treated with caution due to the risks of multiple 
statistical testing. The critical finding of our study is that few of the subgroup analyses showed a 
statistically significant interaction indicating a true difference in treatment response. Even though we 
pooled the results of 3 randomized trials, the total number of 341 subjects most likely still did not 
provide sufficient statistical power to detect all but very large subgroup effects.  
With the caveat that such differences are numerical rather than statistically significant, we observed the 
largest relative treatment effects in older patients, with a history of 1-2 exacerbations per year, a body 
mass index above 30kg/m2, a high baseline C-reactive protein, P. aeruginosa infection and aetiology 
other than idiopathic and post-infective.  
The European Respiratory Society guidelines recommend consideration of macrolide treatment in 
patients with 3 or more exacerbations per year.7 Our finding of a strong treatment benefit in patients 
with a lower frequency of exacerbations suggests that macrolides might be considered in patients with 
1-2 exacerbations per year, particularly if alternative approaches to reduce exacerbations have been 
unsuccessful.7 No quality of life or lung function benefits were observed in this subgroup, however. We 
found no evidence that the response to macrolides was modified by the presence of P. aeruginosa in 
sputum. P. aeruginosa is a key pathogen in bronchiectasis as it is linked to a higher frequency of 
exacerbations, hospital admissions and risk of mortality.27 Prophylactic antibiotics are widely used in 
these patients in view of this increased morbidity.28 Serisier et al reported in the original BLESS trial a 
non-significant trend towards greater efficacy of erythromycin in patients with P. aeruginosa.14 This has 
been interpreted and misinterpreted by some to suggest that macrolides are most effective in patients 
with P. aeruginosa or that macrolides are ineffective in patients without P. aeruginosa.29,30 Our study is 
limited by sample size as only 61 patients out of the 341 subjects had P. aeruginosa with 34 of these 
coming from the BLESS trial. Nevertheless, it is clear that macrolides are effective in patients without P. 
aeruginosa with a statistically significant 52% reduction in the frequency of exacerbations and positive 
effect estimates for quality of life in this subgroup. The estimated effect in patients with P. aeruginosa 
infection was a 64% reduction in exacerbation frequency. We also observed no differential response in 
the small subgroup of patients with H. influenzae infection. Current ERS guidelines recommend that 
inhaled antibiotics should be considered first line for exacerbation reduction in patients with P. 
aeruginosa infection.7 The best estimate of inhaled antibiotic efficacy in patients with bronchiectasis is 
an approximate 30% reduction in the frequency of exacerbations and recent randomized trials have 
given mixed or inconsistent results.24,25,31,32 Our data support the use of macrolides in patients with P. 
aeruginosa and in the absence of head to head studies, could be an appropriate first line maintenance 
antibiotic in selected patients. Our results are consistent with the experience of macrolide treatment in 
cystic fibrosis where macrolide treatment reduces exacerbation frequency in both P. aeruginosa 
infected and uninfected patients.33,34  
Older patients were previously identified as a subgroup more responsive to macrolides in COPD and our 
study suggests this may also be the case in bronchiectasis.35 Systematic inflammation is a risk factor for 
exacerbation in patients with bronchiectasis and the anti-inflammatory effects of macrolides have been 
shown to reduce systemic inflammation including C-reactive protein.36 The association between 
increased age, increased systemic inflammation and increased efficacy of macrolides is therefore 
biologically plausible. It is clear, however, that further studies would be required to provide sufficient 
statistical power to confidently identify these patients groups as more responsive to macrolide 
treatment.   
Strengths and limitations 
The strength of our study is the pooling of three high quality double blind randomized trials all of which 
were evaluated as being at low risk of bias. Access to IPD was comprehensive and allowed more detailed 
analysis than has previously been possible in aggregate meta-analysis. The three studies were conducted 
in different regions but showed concordant results across Europe and the Asia/Pacific region, 
strengthening confidence that these results will be generalizable. Our study has limitations. As outlined 
by the EMA guidance for interpretation of subgroup analyses of randomized controlled trials, even if a 
medicine is associated with benefit it will, by chance alone, appear not to work or even harm in some 
category or categories of patients if sufficient multiple tests are performed. We conducted 30 subgroup 
analyses and so at least 1-2 associations would be expected purely by chance. Results of subgroups 
should ideally be confirmed in future randomized studies. Many subgroups were small with very wide 
confidence intervals reflecting the relatively small size of the patient population overall. We were unable 
to evaluate some potential predictors of response such as disease severity according to 
multidimensional scoring systems, because some data required to calculate these scores such as 
radiological extent of disease were not collected in the original trial databases. We pooled two trials of 
azithromycin and one trial of erythromycin. Our study was not designed to evaluate any differences in 
efficacy between these two macrolides. 
The fact that the favourable effect of macrolides now appears to extend beyond the ‘traditional’ 
frequent exacerbator should, however, not serve as a permit to unrestricted use of macrolide 
maintenance treatment in bronchiectasis patients. Macrolides have important adverse effects including 
direct side effects, population risk of antimicrobial resistance, induction of resistance in NTM, 
cardiovascular effects and drug-drug interactions.8 The results of safety evaluation of the 3 trials 
included in our meta-analysis are extensively reported in the primary publications and subsequent 
meta-analyses and so were not the focus of this manuscript. This said, the trend to worse QoL in 
younger patients with non-frequent exacerbations (Fig 2), may very well be a reflection of more side 
effects in this particular subgroup, which would be consistent with the clinical experience of the authors. 
In each individual patient the potential benefit should be carefully balanced against the potential long 
term impact of macrolide treatment. Therefore, when making the decision to start macrolide 
maintenance treatment, international guidelines recommend that protocols for monitoring of adverse 
effects and subsequent response evaluation should be in place, aimed at detection of cardio-, oto- and 
hepatotoxicity. Recent guidelines recommend to withhold macrolide treatment in patients until active 
NTM infection has been excluded and in patients with evidence of a long QT-interval on ECG.  
The longest trial identified in our search was 12 months and the efficacy and safety of macrolides 
beyond 12 months is unknown. Ideally a future randomized controlled trial should be sufficiently large 
to prospectively validate some of the responder subgroups identified in this meta-analysis and should 
have sufficiently long follow-up to establish long term efficacy and safety.  
In conclusion, macrolides significantly reduce the frequency of exacerbations in bronchiectasis, prolong 
the time to next exacerbation and improve quality of life. This effect is evident across all patient 
subgroups including some patient populations such as those with P. aeruginosa where current 
guidelines do not recommend macrolides as first line.   
Contributors  
Study design: JDC, WB, ML, SLT, CW, JA 
Literature Search: JDC, MLC, JA 
Data collection: WB, LJ, MLC, NK, MLM, LDB, CW, JA 
Data analysis: JDC, ML, MLC, JA 
Data interpretation: JDC, WB, ML, ALT, CW, JA 
Drafting the manuscript: JDC, ML, JA 
Revising the manuscript and approval for submission: All authors 
 
Conflict of interest statement  
Professor Chalmers reports grants and personal fees from Glaxosmithkline, Boehringer-Ingelheim, Astrazeneca, 
Pfizer, Bayer Healthcare, Grifols, Napp, Aradigm corporation, and Insmed  outside the submitted work. The other 
authors declared no conflicts of interest. 
REFERENCES 
1.  Chalmers JD, Chotirmall SH. Bronchiectasis: new therapies and new perspectives. Lancet Respir 
Med. February 2018. doi:10.1016/S2213-2600(18)30053-5 
2.  Spinou A, Fragkos KC, Lee KK, et al. The validity of health-related quality of life questionnaires in 
bronchiectasis:  a systematic review and meta-analysis. Thorax. 2016;71(8):683-694. 
doi:10.1136/thoraxjnl-2015-207315 
3.  Chalmers JD, Aliberti S, Filonenko A, et al. Characterization of the “frequent exacerbator 
phenotype” in bronchiectasis. Am J Respir Crit Care Med. 2018;197(11). 
doi:10.1164/rccm.201711-2202OC 
4.  Hill AT, Haworth CS, Aliberti S, et al. Pulmonary exacerbation in adults with bronchiectasis: a 
consensus definition for clinical research. Eur Respir J. 2017;49(6). doi:10.1183/13993003.00051-
2017 
5.  Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, 
microbiome, and disease heterogeneity. Lancet (London, England). 2018;392(10150):880-890. 
doi:10.1016/S0140-6736(18)31767-7 
6.  Boaventura R, Sibila O, Agusti A, Chalmers JD. Treatable traits in bronchiectasis. Eur Respir J. 
2018;52(3). doi:10.1183/13993003.01269-2018 
7.  Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the 
management of adult bronchiectasis. Eur Respir J. 2017;50(3). doi:10.1183/13993003.00629-
2017 
8.  Kelly C, Chalmers JD, Crossingham I, et al. Macrolide antibiotics for bronchiectasis. Cochrane 
database Syst Rev. 2018;3:CD012406. doi:10.1002/14651858.CD012406.pub2 
9.  Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for 
inflammatory airway diseases. Lancet Respir Med. 2013;1(3):262-274. doi:10.1016/S2213-
2600(13)70038-9 
10.  Haworth CS, Bilton D, Elborn JS. Long-term macrolide maintenance therapy in non-CF 
bronchiectasis: evidence and questions. Respir Med. 2014;108(10):1397-1408. 
doi:10.1016/j.rmed.2014.09.005 
11.  Chalmers JD. Macrolide resistance in Pseudomonas aeruginosa: implications for practice. Eur 
Respir J. 2017;49(5). doi:10.1183/13993003.00689-2017 
12.  Chang AB, Grimwood K, White A V, et al. Randomized placebo-controlled trial on azithromycin to 
reduce the morbidity of bronchiolitis in Indigenous Australian infants: rationale and protocol. 
Trials. 2011;12:94. doi:10.1186/1745-6215-12-94 
13.  Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on 
infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT 
randomized controlled trial. JAMA. 2013;309(12):1251-1259. doi:10.1001/jama.2013.1937 
14.  Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on 
pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS 
randomized controlled trial. JAMA. 2013;309(12):1260-1267. doi:10.1001/jama.2013.2290 
15.  Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic 
fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 
(London, England). 2012;380(9842):660-667. doi:10.1016/S0140-6736(12)60953-2 
16.  Valery PC, Morris PS, Byrnes CA, et al. Long-term azithromycin for Indigenous children with non-
cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention 
Study): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med. 
2013;1(8):610-620. doi:10.1016/S2213-2600(13)70185-1 
17.  Gao Y-H, Guan W-J, Xu G, et al. Macrolide therapy in adults and children with non-cystic fibrosis 
bronchiectasis: a systematic review and meta-analysis. PLoS One. 2014;9(3):e90047. 
doi:10.1371/journal.pone.0090047 
18.  Fan L-C, Lu H-W, Wei P, Ji X-B, Liang S, Xu J-F. Effects of long-term use of macrolides in patients 
with non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled trials. BMC 
Infect Dis. 2015;15:160. doi:10.1186/s12879-015-0872-5 
19.  Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N 
Engl J Med. 2011;365(8):689-698. doi:10.1056/NEJMoa1104623 
20.  Schembri S, Williamson PA, Short PM, et al. Cardiovascular events after clarithromycin use in 
lower respiratory tract infections: analysis of two prospective cohort studies. BMJ. 
2013;346:f1235. 
21.  Kelly C, Evans DJ, Chalmers JD, et al. Macrolide antibiotics for non-cystic fibrosis bronchiectasis. 
Cochrane Database Syst Rev. 2016;2016(10). doi:10.1002/14651858.CD012406 
22.  Aliberti S, Masefield S, Polverino E, et al. Research priorities in bronchiectasis: A consensus 
statement from the EMBARC Clinical Research Collaboration. Eur Respir J. 2016;48(3). 
doi:10.1183/13993003.01888-2015 
23.  Stewart LA, Clarke M, Rovers M, et al. Preferred Reporting Items for Systematic Review and 
Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 
2015;313(16):1657-1665. doi:10.1001/jama.2015.3656 
24.  De Soyza A, Aksamit T, Bandel T-J, et al. RESPIRE 1: a phase III placebo-controlled randomised 
trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 
2018;51(1). doi:10.1183/13993003.02052-2017 
25.  Aksamit T, De Soyza A, Bandel T-J, et al. RESPIRE 2: a phase III placebo-controlled randomised 
trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 
2018;51(1). doi:10.1183/13993003.02053-2017 
26.  Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, 
conduct, and reporting. BMJ. 2010;340:c221. doi:10.1136/bmj.c221 
27.  Araújo D, Shteinberg M, Aliberti S, et al. The independent contribution of Pseudomonas 
aeruginosa infection to long-term clinical outcomes in bronchiectasis. Eur Respir J. 2018;51(2). 
doi:10.1183/13993003.01953-2017 
28.  Henkle E, Aksamit TR, Barker AF, et al. Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: 
Results From an NTM Info  & Research Patient Survey and the Bronchiectasis and NTM Research 
Registry. Chest. 2017;152(6):1120-1127. doi:10.1016/j.chest.2017.04.167 
29.  Guan W-J, Huang Y, Chen C-L, Chen R-C, Zhong N-S. Macrolides, mucoactive drugs and adherence 
for the management of bronchiectasis. Eur Respir J. 2018;51(1). doi:10.1183/13993003.01987-
2017 
30.  Chalmers JD, Polverino E. Macrolides, mucoactive drugs and adherence for the management of 
bronchiectasis. Eur Respir J. 2018;51(1). doi:10.1183/13993003.02033-2017 
31.  Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a 
systematic review. Eur Respir J. 2014;44(2):382-393. doi:10.1183/09031936.00018414 
32.  Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with 
bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 
2014;189(8):975-982. doi:10.1164/rccm.201312-2208OC 
33.         Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, 
 Fieberg AY, Accurso FJ, Campbell PW 3rd; Macrolide Study Group. Azithromycin in patients 
 with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled 
 trial. JAMA. 2003 Oct 1;290(13):1749-56. 
34.         Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose 
 LM, Burns JL, Marshall BC, Ratjen F; AZ0004 Azithromycin Study Group. Effect of azithromycin 
 pulmonary function in patients with cystic fibrosis uninfected with  Pseudomonas 
 aeruginosa: a randomized controlled trial. JAMA. 2010 May 5;303(17):1707-15 
35.  Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease 
exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 
2014;189(12):1503-1508. doi:10.1164/rccm.201402-0207OC 
36.  Saleh AD, Chalmers JD, De Soyza A, et al. The heterogeneity of systemic inflammation in 
 bronchiectasis. Respir Med. 2017;127. doi:10.1016/j.rmed.2017.04.009 
 
 
 
 
 
 
 
 
Trials Setting Key inclusion 
criteria 
Age: Mean (standard 
deviation) 
Male:female Macrolide drug 
and dose 
N intervention; 
Control 
Study duration 
BAT- Altenburg 
201313 
14 hospitals in 
the Netherlands 
2008 to 2010 
3 or more 
exacerbations  
Positive sputum 
culture in the year 
prior to baseline 
59.9 (12.3) (active) vs 64.6 
(9.1) (placebo) 
30:53 Azithromycin 
250mg daily 
 
43 
(azithromycin) 
vs 40 
(Placebo)* 
12 months 
(with 3 months 
run-out 
period) 
BLESS- Serisier 201314 Single centre, 
Australia 2008-
2011 
2 or more 
exacerbations  
Daily sputum 
production 
61.1 (10.5) (active) vs 63.5 
(9.5) (placebo) 
46:71 Erythromycin 
ethylsuccinate 
400mg twice 
daily 
59 
(erythromycin ) 
vs 58 (placebo) 
48 weeks with 
a 4 week 
washout 
period 
EMBRACE- Wong 
201215 
Three centres in 
New Zealand 
2008-2009.  
1 or more 
exacerbation in the 
previous year 
60.9 (13.6) (active) vs 59.0 
(13.3) (placebo) 
43:98 Azithromycin 
500mg three 
times per week 
71 
(azithromycin) 
vs 70 (placebo) 
6 months 
treatment 
period 
followed by 6 
months 
observation 
without 
treatment. 
Table 1. Characteristics of the included studies  
*note that 2 patients in the azithromycin group and 4 patients in the placebo group were excluded 
after randomization before receiving the first dose of drug. These patients were not included in the 
IPD analysis.  
 
 
 
 N (Macrolide vs placebo) Incident rate ratio (95% CI) p-value p-interaction 
Age groups  
<50 years  
50-69 years  
70 years or more. 
Sex 
male  
female 
Prior exacerbation  
1-2 per year 
3 per year  
4 or more per year 
Smoking status  
Never  
Former  
Current 
Inhaled corticosteroid use  
Yes 
No 
Body mass index at baseline 
<21  
21-24.9  
25-29.9 
30 or more 
Aetiology  
idiopathic and post-infective 
Other 
Baseline C-reactive protein 
<2mg/L  
2-5mg/L  
5.1-10mg/L 
>10mg/L 
Baseline FEV1 
>80% predicted  
 
53 (27 vs 26) 
211 (110 vs 101) 
77 (36 vs 41) 
 
119 (59 vs 60) 
222 (114 vs 108) 
 
73 (37 vs 36) 
85 (48 vs 37) 
183 (88 vs 95) 
 
222 (115 vs 107) 
112 (56 vs 56) 
7 (2 vs 5) 
 
223 (112 vs 111) 
118 (61 vs 57) 
 
38 (20 vs 18) 
179 (92 vs 87) 
65 (36 vs 29) 
59 (25 vs 34)  
 
267 (149 vs 118) 
74  (24 vs 50) 
 
98 (49 vs 49) 
95 (51 vs 44) 
71 (36 vs 35) 
60 (30 vs 30) 
 
137 (64 vs 73) 
 
0.61 (0.27-1.37) 
0.52 (0.36-0.76) 
0.36 (0.18-0.71) 
 
0.59 (0.35-0.99) 
0.43 (0.29-0.62) 
 
0.37 (0.16-0.88) 
0.62 (0.32-1.20) 
0.52 (0.36-0.77) 
 
0.51 (0.35-0.74) 
0.44 (0.27-0.73) 
Not estimable 
 
0.49 (0.34-0.71) 
0.44 (0.26- 0.75) 
 
0.36 (0.13-1.02) 
0.56 (0.37-0.84) 
0.55 (0.27-1.10) 
0.27 (0.12-0.61) 
 
0.56 (0.39-0.80) 
0.23 (0.11-0.52) 
 
0.60 (0.34-1.03) 
0.52 (0.30-0.92) 
0.33 (0.15-0.73) 
0.35 (0.17-0.76) 
 
0.52 (0.32-0.84) 
 
0.23 
0.001 
0.003 
 
0.047 
<0.0001 
 
0.025 
0.072 
0.001 
 
<0.0001 
0.002 
n/a 
 
<0.0001 
0.003 
 
0.054 
0.005 
0.093 
0.001 
 
0.002 
<0.0001 
 
0.065 
0.023 
0.006 
0.008 
 
0.008 
 
 
0.18 
 
 
0.31 
 
 
 
0.86 
 
 
 
0.64 
 
 
0.46 
 
 
 
0.50 
 
 
 
0.034 
 
 
 
0.27 
 
 
 
 
50-79% predicted 
<50% predicted 
SGRQ total score  
<30  
30-49  
50 or more 
Pseudomonas aeruginosa  
Yes 
No  
144 (82 vs 62) 
60 (27 vs 33) 
 
139 (72 vs 67) 
123 (64 vs 59) 
79 (37 vs 42) 
 
61 (31 vs 30) 
280 (142 vs 138) 
0.43 (0.27-0.70) 
0.55 (0.27-1.12) 
 
0.50 (0.29-0.84) 
0.45 (0.27-0.74) 
0.50 (0.28-0.90) 
 
0.36 (0.18-0.72) 
0.53 (0.38-0.74) 
0.001 
0.10 
 
0.008 
0.002 
0.022 
 
0.004 
<0.0001 
0.51 
 
 
 
0.90 
 
 
0.45 
 
 
Table 2. subgroup analysis of exacerbation frequency.  
 
 Hazard ratio (95% CI) p-value p-interaction 
Age groups  
<50 years  
50-69 years  
70 years or more. 
Sex 
male  
female 
Prior exacerbation  
1-2 per year 
3 per year  
4 or more per year 
Smoking status  
Never  
Former  
Inhaled corticosteroid use  
Yes 
No 
Body mass index at baseline* 
<21  
21-24.9  
25-29.9 
30 or more 
Aetiology  
idiopathic and post-infective 
Other 
Baseline C-reactive protein* 
<2mg/L  
2-5mg/L  
5.1-10mg/L 
 
0.65 (0.29-1.44) 
0.50 (0.35-0.72) 
0.24 (0.11-0.54) 
 
0.57 (0.34-0.95) 
0.38 (0.27-0.55) 
 
0.40 (0.17-0.96) 
0.47 (0.25-0.89) 
0.48 (0.34-0.69) 
 
0.49 (0.34-0.72) 
0.37 (0.22-0.58) 
 
0.44 (0.31-0.63) 
0.46 (0.27-0.76) 
 
0.22 (0.07-0.70) 
0.56 (0.38-0.82) 
0.33 (0.17-0.67) 
0.26 (0.11-0.59) 
 
0.53 (0.38-0.75) 
0.29 (0.15-0.57) 
 
0.61 (0.35-1.05) 
0.44 (0.26-0.76) 
0.27 (0.12-0.57) 
 
0.29 
<0.0001 
<0.0001 
 
0.030 
<0.0001 
 
0.040 
0.020 
<0.0001 
 
<0.0001 
<0.0001 
 
<0.0001 
0.003 
 
0.010 
0.003 
0.002 
0.001 
 
<0.0001 
<0.0001 
 
0.072 
0.003 
0.001 
 
 
0.15 
 
 
0.22 
 
 
 
0.45 
 
 
0.34 
 
 
0.89 
 
 
0.24 
 
 
 
 
0.11 
 
 
0.20 
 
 
>10mg/L 
Baseline FEV1 
>80% predicted  
50-79% predicted 
<50% predicted 
SGRQ total score  
<30  
30-49  
50 or more 
Pseudomonas aeruginosa  
Yes 
No  
0.39 (0.19-0.82) 
 
0.49 (0.31-0.77) 
0.37 (0.23-0.59) 
0.54 (0.27-1.09) 
 
0.60 (0.37-0.98) 
0.37 (0.24-0.59) 
0.42 (0.23-0.77) 
 
0.36 (0.19-0.69) 
0.47 (0.34-0.65) 
0.013 
 
0.002 
<0.0001 
0.087 
 
0.039 
<0.0001 
0.004 
 
0.001 
<0.001 
 
 
0.86 
 
 
 
0.21 
 
 
 
0.47 
Table 3. Time to first exacerbation subgroup analysis 
 
 
 
FIGURE LEGENDS 
Figure 1. Flow chart of studies included in the IPD meta-analysis. 
 
Figure 2. Forest plot showing impact of macrolide treatment on the change in quality of life using the 
SGRQ total score in the one-step meta-analysis. Abbreviations ICS= inhaled corticosteroid, CRP= C-
reactive protein, FEV1= forced expiratory volume in 1 second, SGRQ= St.Georges Respiratory 
Questionnaire 
 
Figure 3. Forest plot showing impact of macrolide treatment on the change in forced expiratory volume 
in 1 second in the one-step meta-analysis. Abbreviations ICS= inhaled corticosteroid, CRP= C-reactive 
protein, FEV1= forced expiratory volume in 1 second, SGRQ= St.Georges Respiratory Questionnaire 
 
